comparemela.com

Latest Breaking News On - Gigi feng - Page 3 : comparemela.com

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation of patients immune system against cancer cells..

United statesHong kongQing zhouLong wuSan diegoAndrew zhuRichard yehGigi fengGuangdong academy of medical sciencesExchange commissionPrnewswire the company nasdaqGuangdong lung cancer instituteAmerican society of clinical oncologyClinical oncologyPrincipal investigatorGuangdong provincial people

I Mab : Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 - Form 6-K

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022 · . | May 1, 2023

United statesHong kongSouth koreaSan diegoAndrew zhuJingwu zangGenexine neoimmunetechRichard yehGigi fengCorporate developmentEuropean society for medical oncologyUs public company accounting oversight boardMorgan stanley capital internationalWomen leadership councilTracon pharmaceuticalsExchange rate information

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

/PRNewswire/ I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization.

United statesQing zhouHong kongSan diegoMccormick placeGigi fengRichard yehExchange commissionMccormick place convention centerPrnewswire the company nasdaqAmerican society of clinical oncologyClinical oncologyAnnual meetingToripalimab combination therapyTrial results usingPotential predictive

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute Tribunal completely denied Tracon s.

San diegoUnited statesHong kongRichard yehGigi fengMichael sitrick los angelesAndrew zhuExchange commissionPrnewswire the company nasdaqPharmaceuticals traconBsab agreementSecurities litigation reform actOperating officerChief financialLos angelesNew york

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company co.

United statesHong kongSan diegoGigi fengRichard yehAndrew zhuExchange commissionInternational prognostic scoring systemCompany nasdaqRevised international prognostic scoring systemMab forward looking statementsPrivate securities litigation reform actOperating officerChief financial officer

vimarsana © 2020. All Rights Reserved.